<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lung transplantation: General guidelines for recipient selection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lung transplantation: General guidelines for recipient selection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lung transplantation: General guidelines for recipient selection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramsey R Hachem, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert M Kotloff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The most common indications for lung transplantation are interstitial lung disease (ILD), advanced chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH) [<a href="#rid1">1,2</a>]. These account for approximately 85 percent of all procedures performed worldwide. The remaining 15 percent consist of a variety of diagnoses that span the spectrum of end-stage lung disease from sarcoidosis to lymphangioleiomyomatosis (LAM) to pulmonary Langerhans cell histiocytosis [<a href="#rid3">3-8</a>].</p><p>The indications and general guidelines for recipient selection will be presented here. An overview of lung transplantation, the international guidelines for recipient selection, disease-specific indications, and choice of procedure are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL GUIDELINES</span><span class="headingEndMark"> — </span>Lung transplantation should be considered for patients with advanced lung disease whose clinical status has progressively declined despite maximal medical or surgical therapy. Candidates are usually symptomatic during activities of daily living and have a limited life expectancy over the next two years [<a href="#rid9">9,10</a>]. In addition, the ideal candidate should be free of any other organ dysfunction or medical problem that would substantially jeopardize the outcome of lung transplantation.</p><p class="headingAnchor" id="H495544666"><span class="h2">Recipient selection</span><span class="headingEndMark"> — </span>The International Society of Heart and Lung Transplantation (ISHLT) guidelines for recipient selection for lung transplant have been updated and include the following description of suitable candidates [<a href="#rid11">11</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Clinically and physiologically advanced lung disease for which medical therapy is ineffective or unavailable </p><p class="bulletIndent1"><span class="glyph">●</span>High risk (&gt;50 percent) of death from lung disease without transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>High likelihood (&gt;80 percent) of surviving at least five years after lung transplantation, provided graft function is adequate </p><p></p><p class="headingAnchor" id="H4"><span class="h2">Contraindications and risk factors for poor outcomes</span><span class="headingEndMark"> — </span>The 2021 ISHLT guidelines, which were developed by consensus and expert opinion, advise evaluating potential candidates for the presence of risk factors for poor post-transplant outcomes [<a href="#rid11">11</a>]. Certain risk factors for a poor outcome are felt to be absolute or relative contraindications to lung transplantation and others increase the risk of a poor outcome, particularly when present in combination with other risk factors.</p><p class="headingAnchor" id="H951597073"><span class="h3">Absolute contraindications</span><span class="headingEndMark"> — </span>Absolute contraindications include the following [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of patient willingness or acceptance of transplant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Septic shock; active extrapulmonary or disseminated infection; active tuberculosis infection; HIV infection with detectable viral load (see <a class="local">'HIV infection'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy with a high risk of recurrence or death related to the cancer (see <a class="local">'Malignancy'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant dysfunction of other vital organs:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glomerular filtration rate &lt;40 mL/min/1.73 m<sup>3</sup> unless being considered for multiorgan transplant; acute kidney failure with rising creatinine or on dialysis with low likelihood of recovery</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stroke within 30 days or progressive cognitive impairment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute liver failure or cirrhosis with portal hypertension or synthetic dysfunction unless being considered for multi-organ transplant</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute coronary syndrome or myocardial infarction within 30 days (excluding demand ischemia) or significant coronary heart disease not amenable to revascularization (see <a class="local">'Coronary heart disease'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Untreatable hematologic disorders including bleeding diathesis, thrombophilia, or severe bone marrow dysfunction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active substance use or dependence including current tobacco use, vaping, cannabis smoking, or intravenous drug use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited functional status (eg, nonambulatory) with poor potential for post-transplant rehabilitation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeated episodes of nonadherence without evidence of improvement (Note: Not an absolute contraindication for pediatric patients, and ongoing assessment of nonadherence should occur as they progress through different developmental stages.)</p><p></p><p class="headingAnchor" id="H2546247652"><span class="h3">Factors with high or substantially increased risk</span><span class="headingEndMark"> — </span>Patients with certain risk factors for high or substantially increased likelihood for a poor outcome may be considered for transplant at centers with special expertise in managing the particular conditions. However, when more than one of these risk factors are present, the risk may be prohibitive. These risk factors include the following [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;70 years (see <a class="local">'Recipient age'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe coronary artery disease that requires coronary artery bypass grafting at the time of transplant; reduced left ventricular ejection fraction &lt;40 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant cerebrovascular disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMI ≥35 kg/m<sup>2</sup>; BMI &lt;16 kg/m<sup>2</sup> (see <a class="local">'Nutritional status'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia, leukopenia, or anemia with high likelihood of persistence after transplant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe esophageal dysmotility</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest wall or spinal deformity expected to cause restriction after transplant; previous thoracic surgery; previous pleurodesis (see <a class="local">'Previous cardiothoracic surgery'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonization or infection with highly resistant or highly virulent bacteria, fungi, and certain strains of mycobacteria (see <a class="local">'Cystic fibrosis and bronchiectasis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection with <em>Mycobacterium abscessus; Lomentospora prolificans (</em>formerly<em> Scedosporium prolificans</em>)<em>; Burkholderia cenocepacia or gladioli</em> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B or C viral infection with detectable viral load and liver fibrosis (see <a class="local">'Hepatitis B or C infection'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited functional status with potential for post-transplant rehabilitation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric, psychologic, or cognitive conditions with potential to interfere with medical adherence without sufficient support or caregiving systems; lack of understanding of disease and/or lung transplantation despite teaching</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retransplant &lt;1 year after initial lung transplant; retransplant for restrictive chronic lung allograft dysfunction (CLAD); retransplant for antibody mediated rejection as etiology for CLAD</p><p></p><p class="headingAnchor" id="H2116244005"><span class="h3">Unfavorable risk factors</span><span class="headingEndMark"> — </span>The ISHLT identified an additional set of risk factors that have unfavorable implications for short and/or long-term outcomes [<a href="#rid11">11</a>]. Transplant programs may consider patients with these risk factors when present in isolation, but find the candidate unacceptable when multiple risk factors are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Age 65 to 70 years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular comorbidities (see <a class="local">'Coronary heart disease'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild to moderate coronary artery disease</p><p class="bulletIndent2"><span class="glyph">•</span>Severe coronary artery disease that can be revascularized via percutaneous coronary intervention prior to transplant</p><p class="bulletIndent2"><span class="glyph">•</span>Prior coronary artery bypass grafting</p><p class="bulletIndent2"><span class="glyph">•</span>Reduced left ventricular ejection fraction 40 to 50 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral vascular disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular filtration rate 40 to 60 mL/min/1.73 m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes that is poorly controlled (see <a class="local">'Diabetes mellitus'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteoporosis (see <a class="local">'Osteoporosis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal dysmotility; severe gastroesophageal reflux disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional risk factors: BMI 30 to 34.9 kg/m<sup>2</sup> or BMI 16 to 17 kg/m<sup>2</sup>; hypoalbuminemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia, leukopenia, or anemia with high likelihood of persistence after transplant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatic diseases (scleroderma, lupus, inflammatory myopathies)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection with undetectable viral load (see <a class="local">'HIV infection'</a> below); <em>Scedosporium apiospermum</em> infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frailty</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Edible cannabis use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior thoracic surgery; prior pleurodesis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical ventilation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retransplant for obstructive CLAD &gt;1 year after transplantation </p><p></p><p class="headingAnchor" id="H1106155515"><span class="h2">Timing of referral</span><span class="headingEndMark"> — </span>The referral and evaluation process for transplantation takes time, and ideally this process is completed before the patient becomes critically ill or the need for transplantation becomes urgent. Thus, whenever possible, patients with a progressive lung disease should be referred to a transplant center when they are still able to undergo the standard, relatively extensive multidisciplinary evaluation to determine the potential risks and benefits of lung transplantation in their case. Early referral may identify modifiable risk factors that would influence a patient's candidacy for transplantation or their outcome after transplantation. For example, a patient with class I obesity would have more time to lose weight or a patient with deconditioning could enroll in pulmonary rehabilitation to improve their functional status before listing for transplantation. </p><p>Referral to a transplant center does not mean that the patient will necessarily be listed for transplant. Following the evaluation, the patient, patient's family, and transplant specialists will determine together whether placing the patient on the transplant list would be appropriate.</p><p>Clinical settings outlined by the ISHLT as appropriate for referral for transplantation evaluation vary based on the underlying disease and include the following [<a href="#rid11">11</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease (COPD) that is progressive despite smoking cessation, optimization of medications, pulmonary rehabilitation, and supplemental oxygen; a BODE (<strong>B</strong>ody mass index, airflow <strong>O</strong>bstruction, <strong>D</strong>yspnea and <strong>E</strong>xercise capacity) index of 5 to 6 (<a class="calc calc_professional" href="/z/d/html/13448.html" rel="external">calculator 1</a>); or a forced expiratory volume in one second (FEV<sub>1</sub>) &lt;25 percent of predicted. (See  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Lung transplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At the time of a confident radiographic diagnosis of idiopathic pulmonary fibrosis (IPF) or a histologic diagnosis of IPF or fibrosing nonspecific interstitial pneumonia (NSIP), regardless of lung function. (See  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Indications and choice of procedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial lung disease (ILD) associated with rheumatic disease, sarcoidosis, or pulmonary Langerhans cell histiocytosis and New York Heart Association (NYHA) functional class III or IV (ie, symptoms with minimal exertion or severe limitation with symptoms at rest) or rapidly progressive respiratory impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with ILD, additional parameters at which a transplantation evaluation would be appropriate include a forced vital capacity (FVC) &lt;80 percent predicted, a diffusing capacity for carbon monoxide (DLCO) &lt;40 percent predicted, or the requirement for supplemental oxygen, at rest or with exertion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early consideration of referral for transplantation in patients with pulmonary arterial hypertension (PAH) is advised. The ISHLT recommends use of the European Society of Cardiology/European Respiratory Society (ESC/ERS) and the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) models to risk stratify patients [<a href="#rid11">11-13</a>]. Patients who cannot achieve a low-risk status within six months of aggressive therapy should be referred for transplant evaluation [<a href="#rid11">11,13,14</a>]. Patients with pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis should be evaluated at the time of diagnosis. (See  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Lung transplantation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Cystic Fibrosis Foundation updated its guidelines for the referral of patients with CF in 2019 [<a href="#rid15">15</a>]. In general, the new guidelines recommend referral at an earlier stage in the disease course to allow patients and their families to better prepare for transplantation medically and psychologically. Early referral provides sufficient time to modify certain risk factors that may improve a patient's candidacy for transplantation or their post-transplant outcome  (<a class="graphic graphic_table graphicRef121061" href="/z/d/graphic/121061.html" rel="external">table 1</a>). (See <a class="local">'Cystic fibrosis and bronchiectasis'</a> below and  <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Indications for referral to a lung transplant center'</a>.)</p><p></p><p class="headingAnchor" id="H3053637166"><span class="h2">Evaluation of potential lung transplant candidates</span><span class="headingEndMark"> — </span>Lung transplant centers evaluate potential lung transplant candidates to identify any factors that would adversely impact the success of lung transplantation or that need remediation prior to transplant listing. An example of testing that is often performed during a lung transplant evaluation is provided in the table  (<a class="graphic graphic_table graphicRef106946" href="/z/d/graphic/106946.html" rel="external">table 2</a>). The specific tests vary somewhat depending on the patient's age and medical history and the particular transplant center's protocol.</p><p>Once a candidate has been accepted by a transplant program, a lung composite allocation score (CAS) is calculated  (<a class="graphic graphic_table graphicRef59818" href="/z/d/graphic/59818.html" rel="external">table 3</a>). The LAS is used to determine the candidate's place on the waiting list and likelihood of benefit from lung transplantation (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fdata%2Fallocation-calculators%2Flung-cas-calculator%2F&amp;token=8CWIkpM2hckDb9NZ0y5EDWzsqUo6KO%2BgV2TMBlkj%2FNBmPpE9hyQ04W5A9qLw6gcKqbw%2BP%2BY0EGXbuO9xT%2FfmWjIR5bb8OYh2NhZC8FcxZhw%3D&amp;TOPIC_ID=4658" target="_blank">UNOS CAS calculator</a>). The CAS is described in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">"Lung transplantation: An overview", section on 'Lung allocation'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">SPECIAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>A number of factors that may increase the risk of lung transplant or decrease the expected survival are considered on a case-by-case basis. These factors include age, ventilator dependence, previous cardiothoracic surgery, nutritional status, chronic glucocorticoid use, allosensitization, and psychosocial issues [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H726959136"><span class="h2">Recipient age</span><span class="headingEndMark"> — </span>The ISHLT guidelines consider age &gt;70 years to carry a high risk for poor outcome after lung transplant, although an upper age limit for recipient selection has not been established [<a href="#rid11">11</a>]. Since patients vary enormously at any chronological age, a potential transplant patient's age is not usually a contraindication by itself. Instead, age must be considered in the context of the individual patient's medical comorbidities, overall performance status, and expected outcome.</p><p>The number of lung transplant recipients older than 65 has increased annually in the US; based on Organ Procurement and Transplantation Network (OPTN) data, this age group accounted for 38 percent of all lung transplant recipients in 2020 [<a href="#rid17">17,18</a>]. A separate report found that over 40 percent of all lung transplants performed worldwide from 2006 to mid-2012 were for recipients older than 60 years of age; approximately 10 percent were for recipients older than 65 years of age; and 3 percent were for recipients over 70 years [<a href="#rid11">11</a>]. </p><p>Individuals older than 60 years tend to have shorter survival following lung transplant than younger recipients [<a href="#rid1">1,19-21</a>]. However, not all studies support a worse survival for older recipients. Among 225 patients 70 years or older undergoing primary lung transplant between 2005 and 2012, the risk of mortality at one year was not greater than those age 60 to 69 (HR 1.02, 95% CI 0.71-1.46) [<a href="#rid19">19</a>]. In a separate study, survival statistics for septuagenarians (70s) and sexagenarians (60s) were compared, using data from the United Network for Organ Sharing (UNOS) [<a href="#rid20">20</a>]. Among 543 septuagenarians and 4327 sexagenarians, survivals at one year were 79 percent and 80 percent, respectively, but survival rates at three years (49 versus 64 percent, p&lt;0.001) and five years (28 versus 48 percent, p&lt;0.001) were significantly lower for septuagenarians. </p><p class="headingAnchor" id="H179638494"><span class="h2">Frailty</span><span class="headingEndMark"> — </span>Frailty is characterized by physiologic decline, including features such as weight loss (≥5 percent of body weight in last year), exhaustion, weakness (decreased grip strength), slow walking speed, and decreased physical activity, that exceed what might be expected based on age alone [<a href="#rid22">22</a>]. The specific definition varies and a number of measures of frailty have been developed; one example is provided in the table  (<a class="graphic graphic_table graphicRef114174" href="/z/d/graphic/114174.html" rel="external">table 4</a>). However, an optimal assessment tool has not been determined [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/3010.html" rel="external">"Frailty"</a>.)</p><p>Among patients with advanced lung disease, frailty is associated with a greater risk of death before and after lung transplant [<a href="#rid23">23-26</a>]. In a retrospective cohort analysis of adult lung transplant recipients, 46 of 102 patients (45 percent) met criteria for frailty and had an increased risk of death, adjusted HR 2.24 (95% CI 1.22-4.19) [<a href="#rid24">24</a>]. On the other hand, measures of frailty may improve in some patients in the first six months after lung transplant [<a href="#rid27">27</a>]. Frailty is increasingly recognized as an important comorbidity that impacts waiting list and post-transplant outcomes.   </p><p>Our approach is to identify frail and pre-frail individuals using the Short Physical Performance Battery during the initial evaluation and to incorporate this assessment in determining transplant candidacy. Early identification of frailty can make it amenable to rehabilitation and nutritional support, potentially making frailty a modifiable risk factor. However, studies demonstrating an improvement in frailty indices with rehabilitation and a resultant improvement in post-transplant outcomes have not been done.  </p><p class="headingAnchor" id="H6"><span class="h2">Ventilator dependence and extracorporeal life support</span><span class="headingEndMark"> — </span>Mechanical ventilation and extracorporeal membrane oxygenation (ECMO) are considered risk factors for poor post-transplant outcomes that may be acceptable at centers with special expertise (see <a class="local">'Disease-based considerations'</a> below) using these as a "bridging" strategy for lung transplant candidates who develop respiratory failure while awaiting transplant [<a href="#rid11">11,28-31</a>]. In 2019, 9.6 percent of lung transplant recipients aged 12 years or older in the United States were supported with mechanical ventilation and/or ECMO before transplant [<a href="#rid17">17</a>].</p><p>While invasive mechanical ventilation remains a significant risk factor for mortality after transplant [<a href="#rid11">11</a>], multiple reports have demonstrated that carefully selected candidates requiring invasive mechanical ventilation can have satisfactory short- and long-term outcomes after lung transplant [<a href="#rid16">16,32-37</a>]. However, unstable patients requiring mechanical ventilation before transplant have a significantly worse survival [<a href="#rid38">38</a>].</p><p>When feasible, noninvasive positive pressure ventilation is preferred over invasive ventilation because it obviates the need for sedation, and the patient can remain ambulatory and participate in pulmonary rehabilitation. Multiple studies have confirmed satisfactory outcomes after the use of noninvasive ventilation as a bridge to transplant [<a href="#rid39">39-41</a>].</p><p>ECMO is increasingly being used as a bridge to lung transplant in patients with pulmonary or cardio-pulmonary failure [<a href="#rid11">11,37,42-44</a>]. In 2019, approximately 7 percent of all lung transplant recipients in the United States were supported with ECLS before transplant [<a href="#rid17">17</a>]. Between 2016 and 2020, the 587 patients from the United States bridged to single-organ lung transplant with ECMO demonstrated higher mortality compared with nonbridged recipients (16 versus 10 percent at one year and 35 versus 24 percent at three years) [<a href="#rid45">45</a>]. However, after accounting for other patient- and donor-specific factors, the adjusted increased mortality for patients receiving ECMO was only +8 percent (95% CI -17 to +33 percent), which was not statistically significant. In a separate case series, bridging with ECMO was associated with a greater likelihood of needing postoperative ECMO use [<a href="#rid37">37</a>].</p><p>Carefully selected patients can be supported with venovenous ECMO while awake and off invasive mechanical ventilation [<a href="#rid46">46</a>]. This approach allows patients to undergo physical therapy and maintain an adequate nutritional status.</p><p class="headingAnchor" id="H3953252899"><span class="h2">Previous cardiothoracic surgery</span><span class="headingEndMark"> — </span>Previous cardiothoracic surgery, pleurodesis, or pleurectomy increases the technical difficulty of explanting the native lung and the operative risk of lung transplant but are not contraindications to lung transplantation [<a href="#rid11">11,47</a>]. Among 206 patients who underwent lung transplant after various cardiothoracic surgical procedures, survival was similar at 30 days, one year, and five years for those who had prior cardiothoracic procedures and those who did not, although intensive care unit (ICU) stays were longer for the prior surgery group [<a href="#rid47">47</a>].</p><p>Prior coronary artery bypass grafting (CABG) is considered a risk factor for unfavorable short and/or long-term outcomes following lung transplant [<a href="#rid11">11</a>]. In a series of 14,791 patients transplanted between 2004 and 2013, 292 (2 percent) had previously undergone a CABG and of these, 181 received a single right lung transplant, 68 received a single left lung transplant, and 43 received bilateral lung transplants (BLT) [<a href="#rid48">48</a>]. Prior CABG was a predictor of mortality at one, three, and five years, with an overall hazard ratio of 1.97 (95% CI, 1.23-3). However, the effect was largely due to increased mortality among those who underwent BLT.</p><p>Simple pneumothorax that was treated by closed tube thoracostomy, open lung biopsy, or uncomplicated lobectomy is not usually an impediment to transplantation, but more complex cases, such as pleurodesis, must be individually assessed.</p><p class="headingAnchor" id="H7"><span class="h2">Nutritional status</span><span class="headingEndMark"> — </span>The nutritional status of lung transplant candidates can adversely affect post-transplant survival. Thus, consensus guidelines for recipient selection state that a BMI ≥35 kg/m<sup>2</sup> or &lt;16 kg/m<sup>2</sup> carries a substantially increased risk for poor post-transplant outcomes [<a href="#rid11">11</a>].</p><p>Multiple studies have identified pretransplant obesity as a significant risk for mortality after transplant independent of other risk factors [<a href="#rid49">49-56</a>], including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of the United Network for Organ Sharing (UNOS) database demonstrated a 15 percent higher mortality for overweight recipients (BMI = 25 to 29.9 kg/m<sup>2</sup>) and a 22 percent higher mortality for obese recipients (BMI &gt;30 kg/m<sup>2</sup>) than normal weight recipients [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 512 adult lung transplant recipients, obesity was also an independent risk factor for development of grade 3 primary graft dysfunction within 72 hours of transplant [<a href="#rid57">57</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter study using multivariate analyses to examine the impact of BMI on one-year survival after lung transplant, recipients with class I obesity (BMI 30 to 34.9 kg/m<sup>2</sup>) had similar adjusted survival to normal weight and overweight recipients whereas those with class II or III obesity (BMI ≥35 kg/m<sup>2</sup>) had a significantly increased risk of death [<a href="#rid58">58</a>]. Importantly, this study demonstrated a poor correlation between BMI and adiposity, measured by whole-body dual X-ray Absorptiometry (DEXA), suggesting that BMI is a poor measure of obesity in lung transplant candidates.</p><p></p><p>Low BMI has not been a risk factor for mortality after transplant in the ISHLT registry, although one study found a higher mortality among recipients with a BMI &lt;18.5 kg/m<sup>2</sup> and another found a trend to a higher 90-day mortality among recipients with a BMI &lt;17 kg/m<sup>2</sup> [<a href="#rid49">49,50,55,58</a>]. Nonetheless, multiple series have shown that malnutrition is ominous, especially among patients with cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) [<a href="#rid53">53,59-62</a>]. Aggressive attempts to improve the nutritional status are warranted, but low BMI alone generally should not preclude listing or transplantation.</p><p class="headingAnchor" id="H3191478923"><span class="h2">Allosensitization</span><span class="headingEndMark"> — </span>Antibodies to human leukocyte antigens (HLA), a manifestation of allosensitization, are most commonly induced by blood transfusions, pregnancy, and previous transplant, although some allosensitized patients have no history of such sensitizing events. Allosensitization can make it difficult to find a compatible donor, increasing the waiting time and risk of death on the waiting list [<a href="#rid11">11,63</a>].</p><p>Lung transplant candidates are screened for pre-existing anti-HLA antibodies using solid-phase immunoassays that are highly sensitive and specific. If HLA antibodies are present, there is a risk of hyperacute rejection if the donor expresses the reactive HLA. In addition, even low-level donor-specific anti-HLA antibodies (DSA) that don't result in hyperacute rejection increase the risk of chronic rejection and death after transplant [<a href="#rid64">64</a>]. The methodology of assays used in histocompatibility testing are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">"Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing"</a> and  <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a>.)</p><p>Previous studies suggest that recipients who have a panel reactive antibody (PRA) greater than 25 percent before transplant have an increased risk of death, especially in the early postoperative period [<a href="#rid65">65</a>]. However, improved management techniques appear to have reduced the mortality risk of higher PRA levels, perhaps because more specific and sensitive assays are used to avoid the reactive HLA [<a href="#rid65">65</a>]. In a single-center study of 304 transplants performed from 2006 to 2012, pretransplant allosensitization was not associated with an increased risk of adverse outcomes after transplantation when the reactive HLA were avoided in the donor [<a href="#rid66">66</a>].</p><p>While some centers report poor post-transplant survival among allosensitized recipients [<a href="#rid66">66-69</a>], other centers report comparable overall and chronic lung allograft dysfunction (CLAD)-free survival [<a href="#rid66">66,69,70</a>]. This variability may reflect differences in sensitivity of the assays used to detect HLA antibodies. The optimal tests for identifying and measuring donor-specific antibodies and thresholds for organ acceptance have not been determined [<a href="#rid11">11</a>]. At our center, only donors who do not have the reactive HLA are accepted for allosensitized patients. Although this approach mitigates any risk of allosensitization on post-transplant outcomes, it is associated with a longer waiting time and an increased risk of death on the waitlist for highly allosensitized patients [<a href="#rid63">63,66</a>].</p><p>Regimens to deplete anti-HLA antibodies have been tried in patients waiting for lung transplant, but have not demonstrated consistent benefit [<a href="#rid71">71,72</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, 18 patients with a calculated PRA ≥80 percent were treated prior to lung transplant with a desensitization protocol consisting of plasmapheresis, <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) in an attempt to deplete anti-HLA antibodies and increase the donor pool before transplant, but there were no significant changes in the PRA [<a href="#rid71">71</a>]. Nine of the 18 patients were transplanted during the study period; among these, four received organs from donors who did not have the reactive HLA, three from donors with typing that matched low-level HLA antibodies, and two from donors with reactive HLA based only on past antibody testing. Survival after transplant was comparable to allosensitized recipients who were not treated with this regimen [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent study used a desensitization protocol at the time of transplant, rather than before donor organ acceptance [<a href="#rid72">72</a>]. The protocol consisted of plasmapheresis and <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> intraoperatively and anti-thymocyte globulin postoperatively. Fifty-three patients who had DSA before transplant were treated with this regimen and had similar clinical outcomes as patients who were not allosensitized and those who were allosensitized but did not have DSA. However, only five of the 53 patients who had DSA had a positive direct crossmatch suggesting that the antibody detection threshold may be overly sensitive, and these antibodies may not be clinically significant.</p><p></p><p class="headingAnchor" id="H2696722101"><span class="h2">Psychosocial assessment</span><span class="headingEndMark"> — </span>All lung transplant candidates undergo screening for psychological conditions that might interfere with their post-transplant care [<a href="#rid16">16</a>]. Patients are evaluated for a history of psychiatric problems, substance addiction (eg, alcohol, tobacco, narcotics), and other issues that might cause nonadherence to the medical regimen. A reliable social support system is essential to the success of transplantation. Multiple instruments to assess psychosocial status before transplantation are available, including the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) and the Transplant Evaluation Rating Scale (TERS) [<a href="#rid73">73-75</a>]. These may identify modifiable risk factors that would benefit from intervention before or after transplantation.</p><p class="headingAnchor" id="H1923602338"><span class="h1">ASSESSMENT OF COMORBID DISEASE</span><span class="headingEndMark"> — </span>The presence of certain comorbid diseases may increase the likelihood of peritransplant complications or adversely affect the anticipated benefit of lung transplantation. Thus, an important component of the transplant candidate evaluation is to assess the potential contribution of any comorbid diseases to peritransplant complications and long-term survival. An example of testing done during a lung transplant evaluation is provided in the table  (<a class="graphic graphic_table graphicRef106946" href="/z/d/graphic/106946.html" rel="external">table 2</a>). Lung transplant centers generally prefer to do most of this testing at the transplant center.</p><p class="headingAnchor" id="H10"><span class="h2">Coronary heart disease</span><span class="headingEndMark"> — </span>Many lung transplant candidates are at risk for coronary artery disease because of their age, smoking history, or other risk factors. One series of 453 adults undergoing lung transplant demonstrated an incidence of clinically important coronary artery disease of 21 percent, and 15 percent required revascularization either before or at the time of transplant [<a href="#rid76">76</a>]. Candidates should therefore be screened for occult coronary disease during their pretransplant evaluation.</p><p>At our center, essentially all patients over the age of 45 years undergo angiography. This practice is not uniform among transplant programs. Some employ a noninvasive, provocative test for cardiac ischemia as a screen; if this is negative, coronary angiography is not done. (See  <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a>.)</p><p>Noninvasive screening tests for coronary disease have a high false positive rate in patients with end-stage lung disease [<a href="#rid77">77</a>]. Some experts have advocated reserving angiography for patients with multiple risk factors since the majority without risk factors will have normal coronary arteries [<a href="#rid78">78,79</a>]. However, the value of a negative angiogram should not be underestimated, especially in the perioperative period, when hemodynamics are unstable and nonspecific chest pain, positive troponin values from intraoperative cardiac manipulation, and electrocardiographic abnormalities are common.</p><p>Coronary artery disease is a risk factor for unfavorable outcomes following lung transplant. Carefully selected patients with advanced coronary disease and left ventricular dysfunction may be candidates for heart-lung transplant [<a href="#rid16">16</a>]. Alternatively, percutaneous or surgical revascularization may be an option in selected patients with preserved left ventricular function [<a href="#rid76">76</a>]. Several series have documented satisfactory results with percutaneous revascularization before transplant or concomitant bypass surgery at the time of transplant [<a href="#rid76">76,80,81</a>].</p><p class="headingAnchor" id="H2607066200"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>A history of diabetes mellitus (DM) is common among patients with end-stage lung disease. While it is not considered a contraindication to lung transplantation, poorly controlled DM is a risk factor for poor post-transplant outcomes. Most programs require that blood sugars be under good control (eg, a hemoglobin A1C level of 7 percent or less) and significant end-organ disease may be considered a contraindication. (See  <a class="medical medical_review" href="/z/d/html/1807.html" rel="external">"Measurements of chronic glycemia in diabetes mellitus", section on 'Glycated hemoglobin (A1C)'</a>.)</p><p>Several studies have found reduced survival in patients with comorbid DM [<a href="#rid82">82-85</a>], particularly among patients with poor glycemic control [<a href="#rid86">86</a>]. In a ten-year study of 386 consecutive transplants, DM was associated with a significantly increased risk of mortality (HR 3.96, 95% CI 2.85-5.51) [<a href="#rid85">85</a>]. A retrospective study of 267 lung transplant recipients found that pretransplant diabetes mellitus increased the risk of mortality (1.82-fold increase; 95% CI 1.08-3.06) despite an organized DM management program [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H1000853271"><span class="h2">HIV infection</span><span class="headingEndMark"> — </span>HIV infection with a detectable viral load is considered an absolute contraindication to lung transplant [<a href="#rid11">11</a>]. However, lung transplantation may be acceptable for patients who have an undetectable HIV viral load (&lt;20 copies/mL), a CD4+ lymphocyte count above 200/mm<sup>3</sup>, no current AIDS-defining illness, and demonstrated adherence to antiretroviral therapy [<a href="#rid11">11</a>]. Special expertise is needed to avoid post-transplant drug-drug interactions between immunosuppressive therapy and antiretroviral therapy.</p><p class="headingAnchor" id="H3718844183"><span class="h2">Hepatitis B or C infection</span><span class="headingEndMark"> — </span>Infection with hepatitis B (HBV) or C (HCV) viruses with a detectable viral load and liver fibrosis places a patient at high or substantially increased risk for poor post-transplant outcomes [<a href="#rid11">11,88</a>]. Antiviral therapies for HBV are effective and safe, so HBV infection does not limit lung transplantation in the absence of cirrhosis. Similarly, direct-acting combination antiviral therapy for HCV is effective. It is preferable to treat and cure HCV prior to lung transplant, but patients with detectable HCV without significant liver fibrosis can be treated after transplant [<a href="#rid11">11,89</a>]. </p><p>Notably, two small studies have reported good outcomes after lung transplant from hepatitis C viremic donors into uninfected recipients when the recipients were treated with direct-acting antivirals after transplant [<a href="#rid90">90,91</a>]. This suggests that post-transplant treatment of a viremic recipient may also be curative, but experience with this approach has been limited to date. (See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'HIV, HTLV, and hepatitis viruses'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Age-appropriate and disease-specific screening for cancer should be part of every pre-transplant evaluation [<a href="#rid11">11</a>]. For patients with a previous malignancy, the risk of cancer recurrence affects the appropriateness and timing of lung transplant. Malignancy with a high risk of recurrence or death is an absolute contraindication to lung transplant. In contrast, lung transplant may be an option in patients where the risk of recurrence is deemed to be very low based on the type and stage of cancer and with negative metastatic evaluation [<a href="#rid92">92,93</a>]. A five-year disease-free interval is prudent for most patients with a prior malignancy, particularly hematologic malignancy, sarcoma, melanoma, or cancer of the breast, bladder, or kidney, although a shorter disease-free interval may be appropriate for certain malignancies depending on the stage [<a href="#rid92">92</a>]. Localized non-melanoma skin cancer is generally not considered a contraindication to transplantation. The American Society of Transplantation and International Transplant Skin Cancer Collaborative have offered guidelines for the following cancers based on stage and clinical characteristics [<a href="#rid92">92-94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer  (<a class="graphic graphic_table graphicRef135213" href="/z/d/graphic/135213.html" rel="external">table 5</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Colorectal cancer  (<a class="graphic graphic_table graphicRef135214" href="/z/d/graphic/135214.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef135215" href="/z/d/graphic/135215.html" rel="external">table 7</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Prostate cancer  (<a class="graphic graphic_table graphicRef135216" href="/z/d/graphic/135216.html" rel="external">table 8</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Renal cell carcinoma  (<a class="graphic graphic_table graphicRef135217" href="/z/d/graphic/135217.html" rel="external">table 9</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Bladder cancer  (<a class="graphic graphic_table graphicRef135218" href="/z/d/graphic/135218.html" rel="external">table 10</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Gynecological cancer  (<a class="graphic graphic_table graphicRef135219" href="/z/d/graphic/135219.html" rel="external">table 11</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Lung cancer  (<a class="graphic graphic_table graphicRef135220" href="/z/d/graphic/135220.html" rel="external">table 12</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonmelanoma skin cancer  (<a class="graphic graphic_table graphicRef135144" href="/z/d/graphic/135144.html" rel="external">table 13</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Melanoma  (<a class="graphic graphic_table graphicRef135181" href="/z/d/graphic/135181.html" rel="external">table 14</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic malignancies  (<a class="graphic graphic_table graphicRef135203" href="/z/d/graphic/135203.html" rel="external">table 15</a> and <a class="graphic graphic_table graphicRef135204" href="/z/d/graphic/135204.html" rel="external">table 16</a>)</p><p></p><p>Although we consider the recommendations offered by these guidelines, we tend to be slightly more conservative in practice. Additional caution is appropriate for lung transplantation, as lung recipients historically carry the greatest risk of cancer recurrence due to high levels of post-transplant immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient", section on 'Malignancy'</a>.)</p><p>The effect of prior malignancy on lung transplant outcomes has been examined in observational series, such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Experience with prior hematopoietic and solid organ malignancies</strong> – Among 13,613 lung transplant recipients in the International Society of Heart and Lung Transplantation (ISHLT) registry, proportionate hazard modeling found that pretransplant malignancy was not associated with an increased hazard of mortality at five years; no specific malignancy was associated with a change in the hazard of mortality [<a href="#rid95">95</a>]. These observations suggest that current selection techniques for choosing which patients with pretransplant malignancy are transplanted are successful. </p><p></p><p class="bulletIndent1">Among 111 heart and lung transplant recipients with a prior malignancy, almost 50 percent were due to hematopoietic malignancies. Recurrences were noted in 23 recipients with the majority occurring in those with less than five years since treatment of the tumor [<a href="#rid96">96</a>]. Among eight lung recipients with tumors found incidentally in the explanted lung, six were fatal. This high recurrence rate contrasts with other cases in which unsuspected T1N0M0 non-small cell cancers discovered in the excised native lungs of transplant recipients did not recur [<a href="#rid97">97,98</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung adenocarcinoma-in-situ</strong> – In an analysis of the UNOS registry of lung transplantation as a treatment for adenocarcinoma-in-situ (AIS: previously called bronchioloalveolar cell carcinoma), the five-year survival of 29 patients transplanted for AIS over a 23-year period was similar to the general lung transplant cohort, suggesting that lung transplantation may be a treatment option for carefully selected patients with AIS [<a href="#rid99">99</a>]. Nonetheless, because experience is limited and predictors of a good outcome are unclear, many transplant centers consider AIS a contraindication to lung transplantation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory failure due to prior treatment of acute leukemia</strong> – Children can develop bronchiectasis or bronchiolitis obliterans following treatment of acute leukemia with chemotherapy and radiation, and these pulmonary complications can eventually progress to end-stage lung disease. The experience with lung transplantation in such patients is limited, but one small series noted similar outcomes when patients transplanted following treatment of malignancy were compared with those without a history of malignancy [<a href="#rid100">100</a>].</p><p></p><p class="headingAnchor" id="H1121417176"><span class="h2">Osteoporosis</span><span class="headingEndMark"> — </span>Severe, symptomatic osteoporosis, often a complication of glucocorticoid use, is a risk factor for unfavorable outcomes following lung transplant, particularly if it limits post-transplant mobility and rehabilitation [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a>.)</p><p class="headingAnchor" id="H2289308942"><span class="h1">DISEASE-BASED CONSIDERATIONS</span><span class="headingEndMark"> — </span>Certain features or comorbidities of the underlying lung disease may influence lung transplant candidacy decisions.</p><p class="headingAnchor" id="H3934377229"><span class="h2">Chronic obstructive pulmonary disease (COPD)</span><span class="headingEndMark"> — </span>Patients with emphysema may be considered for lung volume reduction surgery (LVRS), lung transplantation, or both. A discussion of the general indications for lung transplantation in COPD and potential alternative interventions is provided separately. (See <a class="local">'Timing of referral'</a> above and  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Lung Volume Reduction, in select patients with dyspnea'</a> and  <a class="medical medical_review" href="/z/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Lung transplantation'</a>.)</p><p>Patients with advanced COPD, such as those with BODE scores (<a class="calc calc_professional" href="/z/d/html/13448.html" rel="external">calculator 1</a>) in the range of 5 to 6 and a forced expiratory volume in one second (FEV<sub>1</sub>) in the range of 20 to 25 percent predicted, may benefit from referral to a transplant center for initial consultation [<a href="#rid11">11</a>]. Additional but less well-validated factors that may warrant a referral include an increase in BODE index score &gt;1 over the preceding 24 months and an enlarged pulmonary artery diameter with a pulmonary artery-to-aorta diameter &gt;1 on computed tomography (CT).</p><p>Increasing experience with patients who have previously undergone LVRS indicates that subsequent successful lung transplant is possible [<a href="#rid101">101-104</a>]. Among 117 lung transplant recipients at a single center, 52 had previous LVRS; in-hospital mortality was 10 percent with or without prior LVRS [<a href="#rid104">104</a>]. Median survival after transplant was 86 months (95% CI 56-116) among those without prior LVRS and 107 months (95% CI 77-137) with prior LVRS (p = 0.6). (See  <a class="medical medical_review" href="/z/d/html/1430.html" rel="external">"Lung volume reduction surgery in COPD"</a>.)</p><p class="headingAnchor" id="H692569927"><span class="h2">Pulmonary fibrosis associated with telomeropathy</span><span class="headingEndMark"> — </span>General parameters for referral of patients with idiopathic pulmonary fibrosis (IPF) are discussed above and separately. (See <a class="local">'Timing of referral'</a> above and  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Indications and choice of procedure'</a> and  <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders"</a>.)</p><p>The short telomere syndromes are caused by variants in the genes responsible for maintaining telomere length (eg, <em>TERT, TERC, PARN, DKC1, TINF2, RTEL1</em>). These variants are associated with IPF and also with dyskeratosis congenita and hematologic manifestations, such as myelodysplasia. Lung transplant recipients with telomerase mutations appear to be at greater risk for post-transplant hematologic abnormalities, such as anemia and thrombocytopenia, and this may cause greater need for transfusions and adjustment of the immunosuppressive regimen [<a href="#rid105">105-107</a>]. Lung recipients with short telomeres also have an increased risk of serious CMV infection post-transplant, as described separately. (See  <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients", section on 'Risk factors'</a>.)</p><p>While long-term survival following lung transplant in these patients appears feasible, careful assessment of hematologic status is appropriate prior to lung transplant. The effect of telomerase mutations on lung transplantation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">"Treatment of idiopathic pulmonary fibrosis", section on 'Factors that may increase the risk of transplantation'</a>.)</p><p class="headingAnchor" id="H1583643089"><span class="h2">Interstitial lung diseases other than IPF</span><span class="headingEndMark"> — </span>Advanced interstitial lung disease (ILD) due to idiopathic interstitial lung disease (IIP) accounts for approximately 40 percent of lung transplants [<a href="#rid108">108</a>]. Consistent clinical predictors of mortality in non-IPF ILDs include FVC and DLCO decline, hospitalization, frailty, oxygen use, and symptoms; thus, timing of referral and listing for lung transplant should take these factors into account.</p><p class="headingAnchor" id="H3448184317"><span class="h2">Interstitial lung disease with extrapulmonary manifestations</span><span class="headingEndMark"> — </span>Carefully selected patients whose lung disease has extrapulmonary manifestations, such as sarcoidosis, lymphangioleiomyomatosis (LAM), and pulmonary Langerhans cell histiocytosis (PLCH) have had satisfactory results after lung transplant. Recurrent disease in the allograft has been reported (eg, lymphangioleiomyomatosis, PLCH, sarcoidosis), but in general, this has not been clinically significant [<a href="#rid7">7,8,109</a>]. However, in one report of three patients with systemic lupus erythematosus, two patients who had anticardiolipin antibodies died early after transplantation because of recurrent vasculitis [<a href="#rid110">110</a>]. (See  <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy", section on 'Lung transplantation'</a> and  <a class="medical medical_review" href="/z/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Lung transplantation'</a> and  <a class="medical medical_review" href="/z/d/html/4334.html" rel="external">"Pulmonary Langerhans cell histiocytosis", section on 'Lung transplantation'</a>.)</p><p>Systemic sclerosis is often complicated by esophageal dysmotility and gastroesophageal reflux, which predispose lung transplant recipients to aspiration and accelerated graft loss. While carefully selected patients with systemic sclerosis and esophageal dysmotility have had satisfactory results after lung transplant [<a href="#rid111">111-113</a>], ISHLT guidelines consider severe esophageal dysmotility to be a risk factor associated with high or substantially increased risk of a poor outcome, and some centers will not offer lung transplant to these patients [<a href="#rid11">11</a>]. (See <a class="local">'Factors with high or substantially increased risk'</a> above and  <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">"Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Lung transplantation'</a>.)</p><p class="headingAnchor" id="H612476166"><span class="h2">Cystic fibrosis and bronchiectasis</span><span class="headingEndMark"> — </span>The timing of referral of patients with cystic fibrosis (CF) for an evaluation for possible lung transplant is described separately; the appropriate timing for referral of patients with noncystic fibrosis bronchiectasis has not been formally determined. Guidance from the Cystic Fibrosis Foundation emphasizes beginning the process of lung transplant referral well before a patient reaches end-stage lung disease  (<a class="graphic graphic_table graphicRef121061" href="/z/d/graphic/121061.html" rel="external">table 1</a>) [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Indications for referral to a lung transplant center'</a>.)</p><p>Chronic infection is a special issue in patients with bronchiectasis, especially those with cystic fibrosis [<a href="#rid114">114</a>]. Aspergillus species, nontuberculous mycobacteria (NTM), and multidrug-resistant bacteria are frequently cultured from the sputum of patients with end-stage CF [<a href="#rid115">115-117</a>]. In addition, multiple studies have reported infection early after transplantation with the same organisms that were cultured from the recipients' airways before transplantation [<a href="#rid115">115,118-120</a>]. Depending on the organism, pretransplant antimicrobial therapy may be indicated to suppress or eradicate the organism. (See  <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Lung transplant evaluation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergillus and Scedosporium</strong> – <em>Aspergillus</em> species are isolated in sputum cultures from 20 to 50 percent of patients with CF awaiting transplantation. In addition, those colonized with <em>Aspergillus</em> before transplantation have a higher risk of <em>Aspergillus</em> tracheobronchitis and anastomotic infections after transplantation. Therefore, most centers initiate antifungal suppressive therapy when <em>Aspergillus</em> is isolated before or after transplantation [<a href="#rid121">121</a>]. (See  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><em>Scedosporium</em> infection, while less common than <em>Aspergillus</em> species, is also associated with poor outcomes after lung transplant, and some centers consider lung infection with <em>Scedosporium</em> to be a contraindication to lung transplantation [<a href="#rid15">15,122</a>]. Life-long prophylaxis after lung transplant may be prudent [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/z/d/html/2429.html" rel="external">"Treatment of Scedosporium and Lomentospora infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nontuberculous mycobacteria</strong> – NTM infections occur in about 10 to 20 percent of lung transplant recipients [<a href="#rid15">15,115</a>]. CF patients with NTM cultured from sputum before transplantation are at increased risk of infection after transplantation, and the risk was highest among those infected with <em>Mycobacterium abscessus</em> [<a href="#rid115">115</a>]. Thus, all patients with CF who are referred for lung transplantation should be evaluated for NTM [<a href="#rid15">15</a>]. Attempts to eradicate these pathogens before transplantation are prudent, and persistently positive cultures on antimycobacterial treatment are a relative contraindication to transplantation [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidrug-resistant bacteria</strong> – The prevalence of infection or colonization with multidrug-resistant bacteria (eg, <em>Burkholderia</em> species) among patients with CF coming to lung transplantation may be increasing; one series found that over 50 percent harbored at least one pan-resistant organism [<a href="#rid123">123,124</a>]. In addition, those with multidrug-resistant <em>Pseudomonas aeruginosa</em> isolated from the sputum have a more rapid decline in lung function and are more likely to need transplantation [<a href="#rid125">125</a>]. Although several series found no statistically significant difference in survival after transplantation between those with resistant organisms and those with sensitive ones, one multicenter study reported that recipients infected with pan-resistant organisms before transplantation had a significantly worse survival after transplantation than those infected with sensitive organisms [<a href="#rid123">123,126-128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burkholderia species</strong> – Infection with <em>Burkholderia cepacia</em> complex (Bcc) or <em>Burkholderia gladioli</em> is considered a relative contraindication to lung transplantation [<a href="#rid15">15,16</a>]. Many transplant centers consider infection with any Bcc an absolute contraindication to transplantation due to the high risk of recurrent and often lethal infection post-transplant; others consider transplant if there is reasonable expectation of pre- and postoperative control of the infection. (See  <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Indications for referral to a lung transplant center'</a>.)</p><p></p><p class="bulletIndent1">Bcc infection is associated with accelerated decline in lung function, making it even more prevalent among transplant candidates [<a href="#rid129">129-132</a>]. Certain genomovars, or subspecies, may have greater virulence than others. Patients infected with Bcc, subspecies <em>Burkholderia cenocepacia</em> in particular, have significantly worse survival after transplantation compared with uninfected patients with CF, and the increased mortality is directly attributable to Bcc infection. (See  <a class="medical medical_review" href="/z/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Burkholderia cepacia complex'</a>.)</p><p></p><p class="headingAnchor" id="H1197735865"><span class="h2">Lung disease due to COVID-19</span><span class="headingEndMark"> — </span>Some patients with severe coronavirus disease 2019 (COVID-19) develop acute respiratory distress syndrome (ARDS) and are subsequently unable to wean from mechanical ventilation or extra-corporeal membrane oxygenation (ECMO) support. Other patients with milder initial disease may develop fibrotic interstitial lung disease and long-term oxygen dependence. A number of lung transplants have been performed for such patients [<a href="#rid133">133-140</a>].</p><p>For those with ARDS, some groups have reported challenges due to severe pleural adhesions, hilar lymphadenopathy, and increased intraoperative transfusion requirements, with the early post-transplant course notable for increased bleeding, high rates of primary graft dysfunction, and prolonged intensive care unit (ICU) length of stay [<a href="#rid135">135-137</a>]; however one-year mortality and graft survival appear to be similar to that of patients transplanted due to other conditions [<a href="#rid139">139,140</a>]. In addition to screening for other contraindications and adverse risk factors, candidates should be evaluated to ensure that COVID-19 infection has cleared, sufficient time has elapsed for recovery, and the patient is likely to tolerate transplant surgery and immunosuppression. (See <a class="local">'Contraindications and risk factors for poor outcomes'</a> above.)</p><p>Centers that have managed lung transplants in patients with chronic fibrosis post-COVID-19 advise a pretransplant evaluation that includes the following: assessment for ILD predating COVID-19, underlying rheumatic disease, and evidence of progression or lack of improvement in pulmonary function tests, six-minute walk tests, and CT [<a href="#rid133">133</a>]. Patients should participate in pulmonary rehabilitation, and reversable causes of ILD should be treated.</p><p>Two groups have analyzed overlapping cohorts of approximately 400 patients who underwent lung transplantation in the United States for COVID-19-associated end-stage lung disease between March 2020 and August 2022, comprising almost 9 percent of all lung transplants performed during this time period [<a href="#rid139">139,140</a>]. These patients were evenly divided in terms of indication (COVID-ARDS and post-COVID fibrosis). Not surprisingly, those who underwent transplantation for COVID-19-related lung disease were generally younger, more likely to be in the ICU, and more likely to need mechanical ventilation or ECMO support before transplantation than other transplant recipients. Despite longer hospital stays, overall survival over the first 12 months was similar to that seen in patients who received lung transplantation for other causes.</p><p class="headingAnchor" id="H329263387"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122278.html" rel="external">"Society guideline links: Lung transplantation"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common diagnoses for lung transplant</strong> – Advanced chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), emphysema due to alpha-1 antitrypsin deficiency, and pulmonary arterial hypertension (PAH) are the most common diseases that lead to lung transplantation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidisciplinary evaluation </strong>– Patients with progressive lung disease should be referred to a transplant center when they are still able to undergo the relatively extensive, multidisciplinary evaluation to determine the potential risks and benefits of lung transplantation in their case  (<a class="graphic graphic_table graphicRef106946" href="/z/d/graphic/106946.html" rel="external">table 2</a>). Referral may identify modifiable risk factors that would influence a patient's candidacy for transplantation or outcome after transplant. (See <a class="local">'Timing of referral'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guidelines for recipient selection </strong>– A consensus document outlining recommendations for recipient selection for lung transplantation have been developed by the International Society of Heart and Lung Transplantation (ISHLT). This consensus document includes consideration of the severity of the underlying lung disease, likelihood of benefit from lung transplantation, presence of comorbid diseases, age of the candidate, ability to participate in an exercise program, nutritional status, and psychosocial support. (See <a class="local">'General guidelines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for poor outcomes</strong> – A number of clinical characteristics and comorbidities are recognized as risk factors for poor outcomes after lung transplantation; some are considered absolute contraindications to lung transplantation, some may be acceptable at centers with special expertise in managing the particular condition, and others may be acceptable unless the patient has more than one of these risk factors. (See <a class="local">'Contraindications and risk factors for poor outcomes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mechanical ventilation and extracorporeal life support (ECLS) were historically considered relative contraindications to lung transplantation but are increasingly used as a "bridging" strategy for lung transplant candidates who develop respiratory failure while awaiting transplant. (See <a class="local">'Ventilator dependence and extracorporeal life support'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A body mass index (BMI) ≥35 kg/m<sup>2</sup> or &lt;16 kg/m<sup>2</sup> carries a substantially increased risk for poor post-transplant outcomes. Attention to nutrition may be able to modify this risk factor prior to transplantation. (See <a class="local">'Nutritional status'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Many lung transplant candidates have risk factors for coronary heart disease. The value of noninvasive testing, such as exercise testing, may be limited because of the underlying lung disease. We obtain coronary angiography in all candidates age 45 years or older. Good outcomes have been achieved in selected patients who can be revascularized prior to or at the time of lung transplant. (See <a class="local">'Coronary heart disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant dysfunction of other vital organs, as might occur with systemic diseases like systemic sclerosis or sarcoidosis, may contribute to increased risk of poor outcomes post-transplant. Certain other special considerations, like prior cardiothoracic surgery, glucocorticoid use, chronic infection, and allosensitization also influence decisions on appropriateness for lung transplantation. (See <a class="local">'Special considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease-specific considerations</strong> – Additional disease-specific considerations include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carefully selected patients whose advanced lung disease has extrapulmonary manifestations, such as sarcoidosis, lymphangioleiomyomatosis (LAM), and pulmonary Langerhans cell histiocytosis have had satisfactory results after lung transplantation. (See <a class="local">'Interstitial lung disease with extrapulmonary manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Guidance from the Cystic Fibrosis Foundation emphasizes beginning the process of lung transplant referral well before a patient with CF with reaches end-stage lung disease  (<a class="graphic graphic_table graphicRef121061" href="/z/d/graphic/121061.html" rel="external">table 1</a>). (See <a class="local">'Cystic fibrosis and bronchiectasis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant 2021; 40:1060.</a></li><li class="breakAll">International Thoracic Organ Transplant (TTX) Registry Data Slides. Adult Lung Transplantation Statistics 2019. Adult Lung Transplants: Major Diagnoses by Year. https://ishltregistries.org/registries/slides.asp?yearToDisplay=2019 (Accessed on October 11, 2021).</li><li><a class="nounderline abstract_t">Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233.</a></li><li><a class="nounderline abstract_t">Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124:922.</a></li><li><a class="nounderline abstract_t">Milman N, Burton C, Andersen CB, et al. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:222.</a></li><li><a class="nounderline abstract_t">Kpodonu J, Massad MG, Chaer RA, et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant 2005; 24:1247.</a></li><li><a class="nounderline abstract_t">Pechet TT, Meyers BF, Guthrie TJ, et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant 2004; 23:301.</a></li><li><a class="nounderline abstract_t">Dauriat G, Mal H, Thabut G, et al. Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006; 81:746.</a></li><li><a class="nounderline abstract_t">Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest 2005; 127:1006.</a></li><li><a class="nounderline abstract_t">Tuppin MP, Paratz JD, Chang AT, et al. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant 2008; 27:729.</a></li><li><a class="nounderline abstract_t">Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40:1349.</a></li><li><a class="nounderline abstract_t">Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37:67.</a></li><li><a class="nounderline abstract_t">Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest 2019; 156:323.</a></li><li><a class="nounderline abstract_t">Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.</a></li><li><a class="nounderline abstract_t">Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18:321.</a></li><li><a class="nounderline abstract_t">Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1.</a></li><li><a class="nounderline abstract_t">Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2019 Annual Data Report: Lung. Am J Transplant 2021; 21 Suppl 2:441.</a></li><li class="breakAll">https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/# (Accessed on October 06, 2021).</li><li><a class="nounderline abstract_t">Kilic A, Merlo CA, Conte JV, Shah AS. Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score? J Thorac Cardiovasc Surg 2012; 144:1133.</a></li><li><a class="nounderline abstract_t">Hayanga AJ, Aboagye JK, Hayanga HE, et al. Contemporary analysis of early outcomes after lung transplantation in the elderly using a national registry. J Heart Lung Transplant 2015; 34:182.</a></li><li><a class="nounderline abstract_t">Lehr CJ, Blackstone EH, McCurry KR, et al. Extremes of Age Decrease Survival in Adults After Lung Transplant. Chest 2020; 157:907.</a></li><li><a class="nounderline abstract_t">O'Hanlon S, Rechner J. Optimising pre-operative assessment for older people. Anaesthesia 2018; 73:1317.</a></li><li><a class="nounderline abstract_t">Montgomery E, Macdonald PS, Newton PJ, et al. Frailty as a Predictor of Mortality in Patients With Interstitial Lung Disease Referred for Lung Transplantation. Transplantation 2020; 104:864.</a></li><li><a class="nounderline abstract_t">Wilson ME, Vakil AP, Kandel P, et al. Pretransplant frailty is associated with decreased survival after lung transplantation. J Heart Lung Transplant 2016; 35:173.</a></li><li><a class="nounderline abstract_t">Guler SA, Kwan JM, Leung JM, et al. Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Swaminathan AC, McConnell A, Peskoe S, et al. Evaluation of Frailty Measures and Short-term Outcomes After Lung Transplantation. Chest 2023; 164:159.</a></li><li><a class="nounderline abstract_t">Venado A, McCulloch C, Greenland JR, et al. Frailty trajectories in adult lung transplantation: A cohort study. J Heart Lung Transplant 2019; 38:699.</a></li><li><a class="nounderline abstract_t">Kinaschuk K, Bozso SJ, Halloran K, et al. Mechanical Circulatory Support as a Bridge to Lung Transplantation: A Single Canadian Institution Review. Can Respir J 2017; 2017:5947978.</a></li><li><a class="nounderline abstract_t">Todd EM, Biswas Roy S, Hashimi AS, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation: A single-center experience in the present era. J Thorac Cardiovasc Surg 2017; 154:1798.</a></li><li><a class="nounderline abstract_t">Chiumello D, Coppola S, Froio S, et al. Extracorporeal life support as bridge to lung transplantation: a systematic review. Crit Care 2015; 19:19.</a></li><li><a class="nounderline abstract_t">Dellgren G, Riise GC, Swärd K, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation: a long-term study. Eur J Cardiothorac Surg 2015; 47:95.</a></li><li><a class="nounderline abstract_t">Meyers BF, Lynch JP, Battafarano RJ, et al. Lung transplantation is warranted for stable, ventilator-dependent recipients. Ann Thorac Surg 2000; 70:1675.</a></li><li><a class="nounderline abstract_t">Baz MA, Palmer SM, Staples ED, et al. Lung transplantation after long-term mechanical ventilation : results and 1-year follow-up. Chest 2001; 119:224.</a></li><li><a class="nounderline abstract_t">Meertens JH, Van der Bij W, Erasmus ME, et al. Lung transplantation for acute respiratory failure in rapidly progressive idiopathic pulmonary fibrosis. Transpl Int 2005; 18:890.</a></li><li><a class="nounderline abstract_t">Bartz RR, Love RB, Leverson GE, et al. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant 2003; 22:433.</a></li><li><a class="nounderline abstract_t">Vermeijden JW, Zijlstra JG, Erasmus ME, et al. Lung transplantation for ventilator-dependent respiratory failure. J Heart Lung Transplant 2009; 28:347.</a></li><li><a class="nounderline abstract_t">Hayanga AJ, Du AL, Joubert K, et al. Mechanical Ventilation and Extracorporeal Membrane Oxygenation as a Bridging Strategy to Lung Transplantation: Significant Gains in Survival. Am J Transplant 2018; 18:125.</a></li><li><a class="nounderline abstract_t">Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant 2017; 36:1047.</a></li><li><a class="nounderline abstract_t">Efrati O, Modan-Moses D, Barak A, et al. Long-term non-invasive positive pressure ventilation among cystic fibrosis patients awaiting lung transplantation. Isr Med Assoc J 2004; 6:527.</a></li><li><a class="nounderline abstract_t">Hodson ME, Madden BP, Steven MH, et al. Non-invasive mechanical ventilation for cystic fibrosis patients--a potential bridge to transplantation. Eur Respir J 1991; 4:524.</a></li><li><a class="nounderline abstract_t">Vedam H, Moriarty C, Torzillo PJ, et al. Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004; 3:8.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Tobias JD, Tumin D. Center Volume and Extracorporeal Membrane Oxygenation Support at Lung Transplantation in the Lung Allocation Score Era. Am J Respir Crit Care Med 2016; 194:317.</a></li><li><a class="nounderline abstract_t">Tipograf Y, Salna M, Minko E, et al. Outcomes of Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation. Ann Thorac Surg 2019; 107:1456.</a></li><li><a class="nounderline abstract_t">Benazzo A, Schwarz S, Frommlet F, et al. Twenty-year experience with extracorporeal life support as bridge to lung transplantation. J Thorac Cardiovasc Surg 2019; 157:2515.</a></li><li><a class="nounderline abstract_t">Lehr CJ, Schold JD, Arrigain S, Valapour M. New OPTN/UNOS data demonstrates higher than previously reported waitlist mortality for lung transplant candidates supported with ECMO. J Heart Lung Transplant 2023; 42:1399.</a></li><li><a class="nounderline abstract_t">Collaud S, Benden C, Ganter C, et al. Extracorporeal Life Support as Bridge to Lung Retransplantation: A Multicenter Pooled Data Analysis. Ann Thorac Surg 2016; 102:1680.</a></li><li><a class="nounderline abstract_t">Omara M, Okamoto T, Arafat A, et al. Lung transplantation in patients who have undergone prior cardiothoracic procedures. J Heart Lung Transplant 2016; 35:1462.</a></li><li><a class="nounderline abstract_t">McKellar SH, Bowen ME, Baird BC, et al. Lung transplantation following coronary artery bypass surgery-improved outcomes following single-lung transplant. J Heart Lung Transplant 2016; 35:1289.</a></li><li><a class="nounderline abstract_t">Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31:1073.</a></li><li><a class="nounderline abstract_t">Madill J, Gutierrez C, Grossman J, et al. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 2001; 20:288.</a></li><li><a class="nounderline abstract_t">Kanasky WF Jr, Anton SD, Rodrigue JR, et al. Impact of body weight on long-term survival after lung transplantation. Chest 2002; 121:401.</a></li><li><a class="nounderline abstract_t">Sekine Y, Waddell TK, Matte-Martyn A, et al. Risk quantification of early outcome after lung transplantation: donor, recipient, operative, and post-transplant parameters. J Heart Lung Transplant 2004; 23:96.</a></li><li><a class="nounderline abstract_t">Lederer DJ, Wilt JS, D'Ovidio F, et al. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med 2009; 180:887.</a></li><li><a class="nounderline abstract_t">Allen JG, Arnaoutakis GJ, Weiss ES, et al. The impact of recipient body mass index on survival after lung transplantation. J Heart Lung Transplant 2010; 29:1026.</a></li><li><a class="nounderline abstract_t">Benden C, Ridout DA, Edwards LB, et al. Body mass index and its effect on outcome in children after lung transplantation. J Heart Lung Transplant 2013; 32:196.</a></li><li><a class="nounderline abstract_t">Gries CJ, Bhadriraju S, Edelman JD, et al. Obese patients with idiopathic pulmonary fibrosis have a higher 90-day mortality risk with bilateral lung transplantation. J Heart Lung Transplant 2015; 34:241.</a></li><li><a class="nounderline abstract_t">Lederer DJ, Kawut SM, Wickersham N, et al. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011; 184:1055.</a></li><li><a class="nounderline abstract_t">Singer JP, Peterson ER, Snyder ME, et al. Body composition and mortality after adult lung transplantation in the United States. Am J Respir Crit Care Med 2014; 190:1012.</a></li><li><a class="nounderline abstract_t">Snell GI, Bennetts K, Bartolo J, et al. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant 1998; 17:1097.</a></li><li><a class="nounderline abstract_t">Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001; 286:2683.</a></li><li><a class="nounderline abstract_t">Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1856.</a></li><li><a class="nounderline abstract_t">Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005.</a></li><li><a class="nounderline abstract_t">Tague LK, Witt CA, Byers DE, et al. Association between Allosensitization and Waiting List Outcomes among Adult Lung Transplant Candidates in the United States. Ann Am Thorac Soc 2019; 16:846.</a></li><li><a class="nounderline abstract_t">Brugière O, Suberbielle C, Thabut G, et al. Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay. Transplantation 2013; 95:761.</a></li><li><a class="nounderline abstract_t">Shah AS, Nwakanma L, Simpkins C, et al. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008; 85:1919.</a></li><li><a class="nounderline abstract_t">Bosanquet JP, Witt CA, Bemiss BC, et al. The impact of pre-transplant allosensitization on outcomes after lung transplantation. J Heart Lung Transplant 2015; 34:1415.</a></li><li><a class="nounderline abstract_t">Smith JD, Ibrahim MW, Newell H, et al. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation. J Heart Lung Transplant 2014; 33:1074.</a></li><li><a class="nounderline abstract_t">Kim M, Townsend KR, Wood IG, et al. Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med 2014; 189:1234.</a></li><li><a class="nounderline abstract_t">Courtwright AM, Cao S, Wood I, et al. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies. Ann Am Thorac Soc 2019; 16:1131.</a></li><li><a class="nounderline abstract_t">Wang M, Campbell P, Lien DC, et al. Safety of Crossing Donor-specific Antibodies in Lung Transplantation. Transplantation 2023; 107:1172.</a></li><li><a class="nounderline abstract_t">Snyder LD, Gray AL, Reynolds JM, et al. Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant 2014; 14:849.</a></li><li><a class="nounderline abstract_t">Tinckam KJ, Keshavjee S, Chaparro C, et al. Survival in sensitized lung transplant recipients with perioperative desensitization. Am J Transplant 2015; 15:417.</a></li><li><a class="nounderline abstract_t">Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. Psychosomatics 2012; 53:123.</a></li><li><a class="nounderline abstract_t">Chernyak Y, Henderson DR, Teh L, et al. Characterization of the Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) in Lung Transplant Candidates. J Clin Psychol Med Settings 2022; 29:137.</a></li><li><a class="nounderline abstract_t">Nöhre M, de Zwaan M, Bauer-Hohmann M, et al. The Transplant Evaluation Rating Scale Predicts Clinical Outcomes 1 Year After Lung Transplantation: A Prospective Longitudinal Study. Front Psychiatry 2021; 12:704319.</a></li><li><a class="nounderline abstract_t">Koprivanac M, Budev MM, Yun JJ, et al. How important is coronary artery disease when considering lung transplant candidates? J Heart Lung Transplant 2016; 35:1453.</a></li><li><a class="nounderline abstract_t">Henzlova MJ, Padilla ML, Freilich A, et al. Dobutamine thallium 201 perfusion imaging in candidates for lung transplantation. J Heart Lung Transplant 1995; 14:251.</a></li><li><a class="nounderline abstract_t">Leibowitz DW, Caputo AL, Shapiro GC, et al. Coronary angiography in smokers undergoing evaluation for lung transplantation: is routine use justified? J Heart Lung Transplant 1994; 13:701.</a></li><li><a class="nounderline abstract_t">Ben-Dor I, Shitrit D, Kramer MR, et al. Is routine coronary angiography and revascularization indicated among patients undergoing evaluation for lung transplantation? Chest 2005; 128:2557.</a></li><li><a class="nounderline abstract_t">Seoane L, Arcement LM, Valentine VG, McFadden PM. Long-term survival in lung transplant recipients after successful preoperative coronary revascularization. J Thorac Cardiovasc Surg 2005; 130:538.</a></li><li><a class="nounderline abstract_t">Tran T, Kashem MA, Firoz A, et al. Lung transplant survival with past and concomitant cardiac revascularization. J Heart Lung Transplant 2023; 42:1334.</a></li><li class="breakAll">International Society for Heart and Lung Transplantation. Adult lung transplantation statistics 2013. https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry&amp;year=2013 (Accessed on February 18, 2016).</li><li><a class="nounderline abstract_t">Thabut G, Ravaud P, Christie JD, et al. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:1156.</a></li><li><a class="nounderline abstract_t">Plantier L, Skhiri N, Biondi G, et al. Impact of previous cardiovascular disease on the outcome of lung transplantation. J Heart Lung Transplant 2010; 29:1270.</a></li><li><a class="nounderline abstract_t">Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes is a major risk factor for mortality after lung transplantation. Am J Transplant 2014; 14:438.</a></li><li><a class="nounderline abstract_t">Hackman KL, Snell GI, Bach LA. Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients. Transplantation 2017; 101:2200.</a></li><li><a class="nounderline abstract_t">Riou M, Renaud-Picard B, Munch M, et al. Organized Management of Diabetes Mellitus in Lung Transplantation: Study of Glycemic Control and Patient Survival in a Single Center. Transplant Proc 2019; 51:3375.</a></li><li><a class="nounderline abstract_t">Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant 2016; 35:228.</a></li><li><a class="nounderline abstract_t">Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol 2018; 69:810.</a></li><li><a class="nounderline abstract_t">Woolley AE, Singh SK, Goldberg HJ, et al. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med 2019; 380:1606.</a></li><li><a class="nounderline abstract_t">Abdelbasit A, Hirji A, Halloran K, et al. Lung Transplantation from Hepatitis C Viremic Donors to Uninfected Recipients. Am J Respir Crit Care Med 2018; 197:1492.</a></li><li><a class="nounderline abstract_t">Al-Adra DP, Hammel L, Roberts J, et al. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant 2021; 21:460.</a></li><li><a class="nounderline abstract_t">Al-Adra DP, Hammel L, Roberts J, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant 2021; 21:475.</a></li><li><a class="nounderline abstract_t">Zwald F, Leitenberger J, Zeitouni N, et al. Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative (ITSCC). Am J Transplant 2016; 16:407.</a></li><li><a class="nounderline abstract_t">Beaty CA, George TJ, Kilic A, et al. Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation. J Heart Lung Transplant 2013; 32:202.</a></li><li><a class="nounderline abstract_t">Sigurdardottir V, Bjortuft O, Eiskjær H, et al. Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. J Heart Lung Transplant 2012; 31:1276.</a></li><li><a class="nounderline abstract_t">Svendsen CA, Bengtson RB, Park SJ, Shumway SJ. Stage I adenocarcinoma presenting in the pneumonectomy specimen at the time of single lung transplantation. Transplantation 1998; 66:1108.</a></li><li><a class="nounderline abstract_t">de Perrot M, Fischer S, Waddell TK, et al. Management of lung transplant recipients with bronchogenic carcinoma in the native lung. J Heart Lung Transplant 2003; 22:87.</a></li><li><a class="nounderline abstract_t">Ahmad U, Wang Z, Bryant AS, et al. Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry. Ann Thorac Surg 2012; 94:935.</a></li><li><a class="nounderline abstract_t">Pechet TV, de le Morena M, Mendeloff EN, et al. Lung transplantation in children following treatment for malignancy. J Heart Lung Transplant 2003; 22:154.</a></li><li><a class="nounderline abstract_t">Burns KE, Keenan RJ, Grgurich WF, et al. Outcomes of lung volume reduction surgery followed by lung transplantation: a matched cohort study. Ann Thorac Surg 2002; 73:1587.</a></li><li><a class="nounderline abstract_t">Shitrit D, Fink G, Sahar G, et al. Successful lung transplantation following lung volume reduction surgery. Thorac Cardiovasc Surg 2003; 51:274.</a></li><li><a class="nounderline abstract_t">Nathan SD, Edwards LB, Barnett SD, et al. Outcomes of COPD lung transplant recipients after lung volume reduction surgery. Chest 2004; 126:1569.</a></li><li><a class="nounderline abstract_t">Inci I, Iskender I, Ehrsam J, et al. Previous lung volume reduction surgery does not negatively affect survival after lung transplantation. Eur J Cardiothorac Surg 2018; 53:596.</a></li><li><a class="nounderline abstract_t">Borie R, Kannengiesser C, Hirschi S, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant 2015; 34:538.</a></li><li><a class="nounderline abstract_t">Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014; 44:178.</a></li><li><a class="nounderline abstract_t">Newton CA, Kozlitina J, Lines JR, et al. Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. J Heart Lung Transplant 2017; 36:845.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1015.</a></li><li><a class="nounderline abstract_t">Milman N, Andersen CB, Burton CM, Iversen M. Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells. Eur Respir J 2005; 26:549.</a></li><li><a class="nounderline abstract_t">Yeatman M, McNeil K, Smith JA, et al. Lung Transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital. J Heart Lung Transplant 1996; 15:144.</a></li><li><a class="nounderline abstract_t">Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000; 5:38.</a></li><li><a class="nounderline abstract_t">Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54:3954.</a></li><li><a class="nounderline abstract_t">Massad MG, Powell CR, Kpodonu J, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005; 29:1510.</a></li><li><a class="nounderline abstract_t">Kotloff RM, Zuckerman JB. Lung transplantation for cystic fibrosis: special considerations. Chest 1996; 109:787.</a></li><li><a class="nounderline abstract_t">Chalermskulrat W, Sood N, Neuringer IP, et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507.</a></li><li><a class="nounderline abstract_t">Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005; 43:3467.</a></li><li><a class="nounderline abstract_t">Bakare N, Rickerts V, Bargon J, Just-Nübling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003; 46:19.</a></li><li><a class="nounderline abstract_t">Quattrucci S, Rolla M, Cimino G, et al. Lung transplantation for cystic fibrosis: 6-year follow-up. J Cyst Fibros 2005; 4:107.</a></li><li><a class="nounderline abstract_t">Nunley DR, Ohori P, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest 1998; 114:1321.</a></li><li><a class="nounderline abstract_t">Helmi M, Love RB, Welter D, et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123:800.</a></li><li><a class="nounderline abstract_t">Husain S, Sole A, Alexander BD, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. J Heart Lung Transplant 2016; 35:261.</a></li><li><a class="nounderline abstract_t">Parize P, Boussaud V, Poinsignon V, et al. Clinical outcome of cystic fibrosis patients colonized by Scedosporium species following lung transplantation: A single-center 15-year experience. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004; 56:277.</a></li><li><a class="nounderline abstract_t">Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23:532.</a></li><li><a class="nounderline abstract_t">Lechtzin N, John M, Irizarry R, et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 73:27.</a></li><li><a class="nounderline abstract_t">Aris RM, Gilligan PH, Neuringer IP, et al. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155:1699.</a></li><li><a class="nounderline abstract_t">De Soyza A, Archer L, Wardle J, et al. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant 2003; 22:764.</a></li><li><a class="nounderline abstract_t">Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26:834.</a></li><li><a class="nounderline abstract_t">Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163:43.</a></li><li><a class="nounderline abstract_t">Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004; 3:93.</a></li><li><a class="nounderline abstract_t">Ledson MJ, Gallagher MJ, Jackson M, et al. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002; 57:142.</a></li><li><a class="nounderline abstract_t">Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104:206.</a></li><li><a class="nounderline abstract_t">King CS, Mannem H, Kukreja J, et al. Lung Transplantation for Patients With COVID-19. Chest 2022; 161:169.</a></li><li><a class="nounderline abstract_t">Bharat A, Machuca TN, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med 2021; 9:487.</a></li><li><a class="nounderline abstract_t">Lang C, Ritschl V, Augustin F, et al. Clinical relevance of lung transplantation for COVID-19 ARDS: a nationwide study. Eur Respir J 2022.</a></li><li><a class="nounderline abstract_t">Razia D, Olson MT, Grief K, et al. Hospitalized patients with irreversible lung injury from COVID-19 have higher morbidity but similar 1-year survival after lung transplant compared to hospitalized patients transplanted for restrictive lung disease. J Heart Lung Transplant 2023; 42:255.</a></li><li><a class="nounderline abstract_t">Bharat A, Querrey M, Markov NS, et al. Lung transplantation for patients with severe COVID-19. Sci Transl Med 2020; 12.</a></li><li><a class="nounderline abstract_t">Kehara H, Mangukia C, Sunagawa G, et al. Lung Transplantation for COVID-19 Pulmonary Sequelae. Transplantation 2023; 107:449.</a></li><li><a class="nounderline abstract_t">Okumura K, Jyothula S, Kaleekal T, Dhand A. 1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019-Associated End-Stage Lung Disease in the United States. Clin Infect Dis 2023; 76:2140.</a></li><li><a class="nounderline abstract_t">Tasoudis P, Lobo LJ, Coakley RD, et al. Outcomes Following Lung Transplant for COVID-19-Related Complications in the US. JAMA Surg 2023; 158:1159.</a></li></ol></div><div id="topicVersionRevision">Topic 4658 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34446355" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34446355" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12114364" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Outcomes for patients with sarcoidosis awaiting lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970018" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predicting mortality in patients with sarcoidosis awaiting lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16315786" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143241" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15019639" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lung transplantation for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534477" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764787" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lung transplantation: disease-specific considerations for referral.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18582801" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34419372" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320113" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30772387" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30926322" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085497" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595190" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : OPTN/SRTR 2019 Annual Data Report: Lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595190" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : OPTN/SRTR 2019 Annual Data Report: Lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22944081" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447584" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Contemporary analysis of early outcomes after lung transplantation in the elderly using a national registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31419403" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Extremes of Age Decrease Survival in Adults After Lung Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29934994" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Optimising pre-operative assessment for older people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31397799" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Frailty as a Predictor of Mortality in Patients With Interstitial Lung Disease Referred for Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679297" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pretransplant frailty is associated with decreased survival after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31537699" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36681147" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evaluation of Frailty Measures and Short-term Outcomes After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31005571" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frailty trajectories in adult lung transplantation: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28951661" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mechanical Circulatory Support as a Bridge to Lung Transplantation: A Single Canadian Institution Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29042051" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Extracorporeal membrane oxygenation as a bridge to lung transplantation: A single-center experience in the present era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25774818" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Extracorporeal life support as bridge to lung transplantation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24659316" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Extracorporeal membrane oxygenation as a bridge to lung transplantation: a long-term study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11093509" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lung transplantation is warranted for stable, ventilator-dependent recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157608" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Lung transplantation after long-term mechanical ventilation : results and 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15948873" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lung transplantation for acute respiratory failure in rapidly progressive idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681421" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332261" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lung transplantation for ventilator-dependent respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28695576" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mechanical Ventilation and Extracorporeal Membrane Oxygenation as a Bridging Strategy to Lung Transplantation: Significant Gains in Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28784324" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15373309" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term non-invasive positive pressure ventilation among cystic fibrosis patients awaiting lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1936222" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Non-invasive mechanical ventilation for cystic fibrosis patients--a potential bridge to transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15463881" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840155" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Center Volume and Extracorporeal Membrane Oxygenation Support at Lung Transplantation in the Lung Allocation Score Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30790550" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcomes of Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30922636" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Twenty-year experience with extracorporeal life support as bridge to lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37150472" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : New OPTN/UNOS data demonstrates higher than previously reported waitlist mortality for lung transplant candidates supported with ECMO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27424471" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Extracorporeal Life Support as Bridge to Lung Retransplantation: A Multicenter Pooled Data Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27773457" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lung transplantation in patients who have undergone prior cardiothoracic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27381675" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lung transplantation following coronary artery bypass surgery-improved outcomes following single-lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22975097" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11257554" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834649" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of body weight on long-term survival after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734133" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk quantification of early outcome after lung transplantation: donor, recipient, operative, and post-transplant parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608717" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Obesity and underweight are associated with an increased risk of death after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558085" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The impact of recipient body mass index on survival after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200225" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Body mass index and its effect on outcome in children after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447567" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Obese patients with idiopathic pulmonary fibrosis have a higher 90-day mortality risk with bilateral lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799077" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25233138" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Body composition and mortality after adult lung transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855449" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730443" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Survival effect of lung transplantation among patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588597" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prognostic value of nutritional status in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999112" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763122" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Association between Allosensitization and Waiting List Outcomes among Adult Lung Transplant Candidates in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23296148" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18498795" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169666" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The impact of pre-transplant allosensitization on outcomes after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24954882" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24749479" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31026404" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36595026" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Safety of Crossing Donor-specific Antibodies in Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24666831" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Antibody desensitization therapy in highly sensitized lung transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612494" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Survival in sensitized lung transplant recipients with perioperative desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424160" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043137" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Characterization of the Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) in Lung Transplant Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34512417" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The Transplant Evaluation Rating Scale Predicts Clinical Outcomes 1 Year After Lung Transplantation: A Prospective Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27266805" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : How important is coronary artery disease when considering lung transplant candidates?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7779843" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Dobutamine thallium 201 perfusion imaging in candidates for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947888" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Coronary angiography in smokers undergoing evaluation for lung transplantation: is routine use justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236923" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Is routine coronary angiography and revascularization indicated among patients undergoing evaluation for lung transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16077424" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term survival in lung transplant recipients after successful preoperative coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37187320" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Lung transplant survival with past and concomitant cardiac revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37187320" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Lung transplant survival with past and concomitant cardiac revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18310481" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20580260" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Impact of previous cardiovascular disease on the outcome of lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24401019" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diabetes is a major risk factor for mortality after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27798516" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31733791" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Organized Management of Diabetes Mellitus in Lung Transplantation: Study of Glycemic Control and Patient Survival in a Single Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26615769" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Impact of donor and recipient hepatitis C status in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29940268" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30946553" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29412687" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Lung Transplantation from Hepatitis C Viremic Donors to Uninfected Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32969590" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32976703" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26820755" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative (ITSCC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23265911" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23089300" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808500" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Stage I adenocarcinoma presenting in the pneumonectomy specimen at the time of single lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531417" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Management of lung transplant recipients with bronchogenic carcinoma in the native lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22835555" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581763" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Lung transplantation in children following treatment for malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12022555" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Outcomes of lung volume reduction surgery followed by lung transplantation: a matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571344" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Successful lung transplantation following lung volume reduction surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15539729" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Outcomes of COPD lung transplant recipients after lung volume reduction surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28957998" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Previous lung volume reduction surgery does not negatively affect survival after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612863" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Severe hematologic complications after lung transplantation in patients with telomerase complex mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24833766" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Lung transplantation in telomerase mutation carriers with pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28262440" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548028" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report-2019; Focus theme: Donor and recipient size match.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135738" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Recurrent sarcoid granulomas in a transplanted lung derive from recipient immune cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8672517" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Lung Transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11147028" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Lung transplantation and systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17133609" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16222454" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Outcomes of lung transplantation in patients with scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8617092" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Lung transplantation for cystic fibrosis: special considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601086" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16000480" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12588478" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914093" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Lung transplantation for cystic fibrosis: 6-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824009" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Pulmonary aspergillosis in cystic fibrosis lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628881" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26970469" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28618155" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Clinical outcome of cystic fibrosis patients colonized by Scedosporium species following lung transplantation: A single-center 15-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15066737" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879776" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113513" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9154879" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12873544" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692788" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208624" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15463892" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11828044" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6420530" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34418410" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Lung Transplantation for Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33811829" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35301249" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Clinical relevance of lung transplantation for COVID-19 ARDS: a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36272894" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Hospitalized patients with irreversible lung injury from COVID-19 have higher morbidity but similar 1-year survival after lung transplant compared to hospitalized patients transplanted for restrictive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33257409" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Lung transplantation for patients with severe COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36525557" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Lung Transplantation for COVID-19 Pulmonary Sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36757715" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : 1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019-Associated End-Stage Lung Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37585215" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Outcomes Following Lung Transplant for COVID-19-Related Complications in the US.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
